TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02924389

Intervention type: DRUG
Group type: OTHER
Intervention: dolutegravir
Description: Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.

Intervention type: DRUG
Group type: OTHER
Intervention: Triumeq
Description: Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Triumeq
Description: Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Truvada
Description: Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
Study: NCT04141891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving Decision Aid
Description: Healthwise DDA

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Older Drivers Website
Description: National Institute on Aging (NIA) Older Drivers Website
Study: NCT00979875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Study: NCT01146379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive task-specific upper extremity rehabilitation
Description: The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive task-specific upper extremity rehabilitation
Description: The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive task-specific upper extremity rehabilitation
Description: The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive task-specific upper extremity rehabilitation
Description: The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
Study: NCT03456206

Intervention type: OTHER
Intervention: Intake of red and processed meat and fibres
Description: The intention is to analyse exposure groups in tertiles: 1) Upper tertile (33.3% of the total sample) based on the ratio: meat/fibre intake is associated with higher risk of CID. 2) Low intake of fibre (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of red and processed meat (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with higher risk of CID, and their synergy (interaction between the factors meat and fibres) gives the highest risk outcome.

Intervention type: OTHER
Intervention: Lifestyle factors independently or combined
Description: Lifestyles factors are defined as: red and processed meat, vegetables, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/fat, protein/fat from red and processed meat, glycemic index.
Study: NCT00789932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: 32 weeks of CBT, 1.5 hours weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual community care
Description: 16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
Study: NCT00184496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: To methods for switching morphine to methadon. Stop-and go versus overlap

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: To methods for switching morphine to methadon. Stop-and go versus overlap
Study: NCT03455569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral sleep education
Description: This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education only
Description: This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
Study: NCT02924389

Intervention type: DRUG
Group type: OTHER
Intervention: Truvada
Description: Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
Study: NCT04223635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
Study: NCT01432912

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Physician Educational Seminar
Description: Participating Physicians will attend an hour long seminar on smoking cessation counselling.
Study: NCT03879980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral QL block
Description: Bilateral lateral Quadratus Lumborum block using 20 ml of 0.25% bupivacaine each injection as preemptive analgesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-QL block
Description: Only received fentanyl IV during surgery.
Study: NCT01287949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, polio and pertussis vaccination
Description: 1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later
Study: NCT02989649

Intervention type: DRUG
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Intervention: Alogliptin FDC With Pioglitazone
Description: Alogliptin FDC with pioglitazone tablets

Intervention type: DRUG
Intervention: Alogliptin FDC With Metformin
Description: Alogliptin FDC with metformin tablets
Study: NCT01966068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyAsthma Web Portal
Description: Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
Study: NCT02195622

Intervention type: DEVICE
Group type: OTHER
Intervention: Lumenis VersaCut Morcellator

Intervention type: DEVICE
Group type: OTHER
Intervention: Wolf Piranha Morcellator
Study: NCT04490044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Under & Over rehabilitation tool
Description: Under \& Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Under & Over rehabilitation tool
Description: Under \& Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Under & Over rehabilitation tool
Description: Under \& Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.
Study: NCT02886234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Description: Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching (HC)
Description: The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
Study: NCT03504371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral erector spinae block
Description: The patient placed in a lateral position and transducer placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony acoustic shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side and preformed in the same way to achieve sensory block T5-T10 .

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Thoracic epidural anesthesia
Description: patients will receive TEA where an epidural catheter will be placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine with 1:200,000 epinephrine will be injected followed by 5-6 ml of bupivacaine 0.25%.
Study: NCT06768502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Based Approach (CBA)
Description: The community-based approach on IPV and sexual violence is conceived as a dynamic process where community members willing to recover from life wounds induced by IPV and sexual violence agree to share their lived experiences in order to work on them accordingly and to support each other in this healing journey.
Study: NCT02825719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Description: Ulipristal acetate 5mg daily will be prescribed
Study: NCT00624195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA Approved Antiretroviral Therapy (see list below)
Description: Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA Approved Antiretroviral Therapy (see list below)
Description: Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir
Study: NCT03413956

Intervention type: PROCEDURE
Intervention: Surgeries
Description: Surgeries
Study: NCT03486678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210+GEMOX
Description: 28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond chemotherapy until the disease progression or untolerable toxicity.
Study: NCT01532843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN alfa-2b
Description: Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
Study: NCT02618837

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Downstream strategy
Description: At diagnosis:~Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel~Pre-procedure:~Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.~In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor~At the time of PCI, the loading doses required (according to randomization):~* Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months~* Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel\* daily for at least 12 months~  * If subject is \>75 years old or \<60 kg, daily dose of prasugrel should be 5mg
Study: NCT02825719

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Placebo pills will be prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous sulphate
Description: Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Description: Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
Study: NCT06057259

Intervention type: DEVICE
Intervention: Joint position sense measurement
Description: The participants' wrist joint position sense was evaluated.
Study: NCT02618837

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upstream strategy
Description: At the time of diagnosis:~Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.~Pre-procedure:~All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.~All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF).
Study: NCT03648125

Intervention type: DEVICE
Group type: OTHER
Intervention: with artificial occlusal disturbance
Description: A silicon artificial occlusal disturbance is made from a mould of the rowers mouth and placed in the mouth during the training session.~With artificial occlusal disturbance : Maximal Intercuspal Occlusion (MIO) with silicone splint increases the vertical dimension of occlusion of 1, 2 and 4 mm.

Intervention type: DEVICE
Group type: OTHER
Intervention: without artificial occlusal disturbance
Description: The training session is performed without occlusal disturbance
Study: NCT02783222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: comparison of different dosages of drug
Study: NCT02202434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: Procedure: Transcatheter aortic valve replacement (TAVR)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: Procedure: Transcatheter aortic valve replacement (TAVR)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: Procedure: Transcatheter aortic valve replacement (TAVR)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: Procedure: Transcatheter aortic valve replacement (TAVR)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoreValve/Evolut R Transcatheter Aortic Valve Replacement System
Description: Procedure: Transcatheter aortic valve replacement (TAVR)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOTUS Edge Valve System
Description: Procedure: Transcatheter aortic valve replacement (TAVR)
Study: NCT00638196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linoleic Acid/Oleic Acid
Description: Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
Study: NCT04374396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real ultrasound-guided single shot erector spinae plane block (ESP B)
Description: ESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~After negative aspiration, 0.3 mL/kg- of bupivacaine 0.25% will be injected confirming correct position by visualizing the solution lifting the ESM off the transverse process .Spread of LA between the L1 and L4 transverse processes will be thereafter visually tracked with the transducer. In the control group, no local anesthetics will be injected.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound-guided single shot erector spinae plane block (ESP B)
Description: EESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~No local anesthetics will be injected